- NCIt
- C9291
Loading cancer entity…
Loading cancer entity…
Clinical trials
88 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06697964 | High Resolution Anuscopy Study | recruiting | — | 500 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05130073 | 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer | completed | — | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04626466 | Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation(MIFADORESOL) | completed | — | 100 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05438836 | Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer(ROAR-A) | recruiting | — | 205 | Herlev HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT03690921 | Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT02402842 | Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma(Epitopes-HPV02) | completed | Phase 2 | 70 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT05374252 | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients | unknown | Phase 3 | 102 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03942900 | Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma(LAND) | withdrawn | — | 0 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01845779 | Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal(Epitopes-HPV01) | completed | N/A | 64 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT03944252 | Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)(CARACAS) | unknown | Phase 2 | 54 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jul 26, 2019 | clinicaltrials |
| NCT01285778 | Vectibix for the Treatment of Anal Cancer(VITAL) | completed | Phase 2 | 58 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03469596 | Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor? | completed | — | 87 | Fondation Hôpital Saint-JosephOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT03465501 | Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates(BOOST-CA) | completed | — | 89 | Institut Paoli-CalmettesOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays | terminated | — | 3 | Castle Biosciences IncorporatedINDUSTRY | 1 | Jan 25, 2018 | clinicaltrials |
| NCT02369939 | Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy(HYCAN) | unknown | Phase 3 | 118 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT03241680 | Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) | unknown | N/A | 80 | Universidade do Vale do SapucaiOTHER | 1 | Aug 7, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00754078 | A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy | unknown | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01843452 | Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal | terminated | Phase 2 | 8 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 19, 2016 | clinicaltrials |
| NCT01115790 | A Phase 1 Study in Participants With Advanced Cancer | completed | Phase 1 | 150 | Eli Lilly and CompanyINDUSTRY | 1 | May 10, 2016 | clinicaltrials |
| NCT02051868 | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel(InterAACT) | unknown | Phase 2 | 80 | Royal Marsden NHS Foundation TrustOTHER | 3 | Nov 4, 2015 | clinicaltrials |
| NCT02162641 | Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer(R-SeNSAR) | withdrawn | — | 0 | The Christie NHS Foundation TrustOTHER | 0 | Jun 3, 2015 | clinicaltrials |
| NCT01877135 | Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients(AIN3) | unknown | — | 1,000 | French Society of ColoproctologyOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01941966 | A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. | completed | Phase 2 | 51 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Feb 19, 2025source: clinicaltrials